The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancer
Authors:
- 20 June 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 16 (8) , 839-852
Abstract
We are yet to identify an accurate, precise and non-invasive biomarker for the detection of prostate cancer. It would undoubtedly be useful to have a reliable and cost-effective biomarker to inform clinical practice, in order to make a non-invasive diagnosis and to predict risk of progression to aggressive prostate cancer. Since the detection of cell-free-circulating-tumor DNA in the body fluids of prostate cancer patients, a number of studies have been conducted to assess diagnostic and/or prognostic information. In this literature review we evaluate the utility of cell-free-circulating-tumor-DNA for the development of a diagnostic and/or prognostic tool for prostate cancer. In addition, we identify potential areas for future research. Results from both quantitative and qualitative studies are presented. Expert commentary: Evidence for the suitability of a panel of DNA methylation markers for the non-invasive diagnosis of prostate cancer is strong. This panel would likely include the assessment of methylation status in gene promoter regions within the EDNR, GSTP1 and MDR genes. TIMP3 and APC show potential as diagnostic markers and should be further researched. Similarly, quantitation of cell-free-circulating-tumor-DNA in blood and urine requires further investigation.Keywords
This publication has 74 references indexed in Scilit:
- Urine Cell-Free DNA Integrity as a Marker for Early Prostate Cancer Diagnosis: A Pilot StudyBioMed Research International, 2013
- DNA Methylation Changes Correlate with Gleason Score and Tumor Stage in Prostate CancerDNA and Cell Biology, 2012
- Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysisBritish Journal of Cancer, 2011
- A systematic review of the diagnostic accuracy of prostate specific antigenBMC Urology, 2009
- Performance of a Single Assay for Both Type III and Type VI TMPRSS2:ERG Fusions in Noninvasive Prediction of Prostate Biopsy OutcomeClinical Chemistry, 2008
- Development of a Multiplexed Urine Assay for Prostate Cancer DiagnosisClinical Chemistry, 2008
- CpG Island Hypermethylation Profile in the Serum of Men With Clinically Localized and Hormone Refractory Metastatic Prostate CancerJournal of Urology, 2008
- Comparison of Genetic Alterations Detected in Circulating Microsatellite DNA in Blood Plasma Samples of Patients with Prostate Cancer and Benign Prostatic HyperplasiaAnnals of the New York Academy of Sciences, 2006
- RASSF2 Is a Novel K-Ras-specific Effector and Potential Tumor SuppressorJournal of Biological Chemistry, 2003
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002